FDA
-
-
-
-
-
-
-
Armata Pharmaceuticals delays Q4 2025 earnings, gets FDA designation
-
-
-
-
-
-
-
Armata Pharmaceuticals Announces Third Quarter 2025 Results and Provides Corporate Update
-
-
-
-
-
-
-
Armata Pharmaceuticals Announces First Quarter 2025 Results and Provides Corporate Update
-
-
-
-
-
-
-
Armata Pharmaceuticals Announces the Completion of Enrollment of its Phase 1b/2a diSArm Study Evaluating Intravenous AP-SA02 as a Potential Treatment for Staphylococcus aureus Bacteremia
-
-
-
-
-
-
-
Armata Pharmaceuticals Announces Clearance of Investigational New Drug Application to Initiate Phase 2 Clinical Trial of AP-PA02 in Non-Cystic Fibrosis Bronchiectasis
-
-
-
-
-
-
-
Armata Pharmaceuticals Issues Letter to Shareholders
-
-
-
-
-
-
-
Armata Pharmaceuticals to Host Key Opinion Leader Meeting on Bacteriophage-Based Therapeutics on June 26 in New York
-
322,212 total articles have been posted to this entity.
Click Here to Sign-Up for StreetInsider.com Premium to View All

